<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892318</url>
  </required_header>
  <id_info>
    <org_study_id>GO30139</org_study_id>
    <nct_id>NCT02892318</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)</brief_title>
  <official_title>A Phase Ib Study Evaluating the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Immunomodulatory Agents in Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is a non-randomized, open-label, Phase Ib study of atezolizumab in combination with
      immunomodulatory agents for the treatment of participants with AML (relapsed/refractory and
      treatment-naive, elderly participants unfit for induction chemotherapy). The study has been
      designed with the intent, over time, to study multiple combinations of atezolizumab with
      different immunomodulatory agents in participants with AML. The study will begin with the
      evaluation of the combination of atezolizumab and guadecitabine (Arm A). In the future,
      additional arms may be added.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study enrollment on hold to evaluate safety and efficacy data.
  </why_stopped>
  <start_date type="Actual">October 31, 2016</start_date>
  <completion_date type="Anticipated">January 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>Baseline up to approximately 32 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Complete Remission (CR) as Defined by International Working Group (IWG) 2003 and European Leukemia Net (ELN) 2010 Response Criteria</measure>
    <time_frame>After 6 cycles of combination therapy (at Week 24; each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Complete Remission with Incomplete Platelet Recovery (CRp) as Defined by IWG 2003 and ELN 2010 Response Criteria</measure>
    <time_frame>After 6 cycles of combination therapy (at Week 24; each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants with Complete Remission with Incomplete Recovery (CRi) as Defined by IWG 2003 and ELN 2010 Response Criteria</measure>
    <time_frame>After 6 cycles of combination therapy (at Week 24; each cycle is 28 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Response as Defined by IWG 2003 and ELN 2010 Response Criteria</measure>
    <time_frame>Baseline until the date of relapse/progression or death from any cause, assessed up to approximately 32 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Best Overall Response as Defined by IWG 2003 and ELN 2010 Response Criteria</measure>
    <time_frame>Baseline until the date of relapse/progression or death from any cause, assessed up to approximately 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free Survival (EFS) as Defined by IWG 2003 and ELN 2010 Response Criteria</measure>
    <time_frame>Baseline until the date of induction treatment failure or relapse or death from any cause, assessed up to approximately 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free Survival (LFS) as Defined by IWG 2003 and ELN 2010 Response Criteria</measure>
    <time_frame>Baseline until the date of relapse or death from any cause, assessed up to approximately 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline until death from any cause, assessed up to approximately 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Minimal Residual Disease (MRD) Negativity in Participants who Achieve CR, CRp, or CRi</measure>
    <time_frame>Baseline up to approximately 32 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Drug Antibody (ADA) to Atezolizumab</measure>
    <time_frame>Pre-infusion (0 hours [hrs]) on Day (D) 1 of Cycle (C) 1; D8 of C2, C3, C4, C6, and every 6 cycles thereafter until treatment discontinuation (up to 32 months); at 120 days and 1 year after atezolizumab last dose (up to 32 months; each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Atezolizumab</measure>
    <time_frame>Day 1 up to 32 months (detailed sample collection time points are provided in Outcome Measure Description)</time_frame>
    <description>Pre-infusion (0 hrs) on D1 of C1, C4; 30 minutes after end of infusion (infusion duration=30-60 minutes) on D8 of C1, C2, C4; Pre infusion (0 hrs) on D22 of C1, D8 of C2, C3, C4, C6, every 6 cycles thereafter until treatment discontinuation (up to 32 months); at 120 days and 1 year after atezolizumab last dose (up to 32 months; each cycle is 28 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Guadecitabine</measure>
    <time_frame>1, 2, 5, and 8 hours post-injection on D1 of C1 and C4, 1 hour post-injection on D1 of C2, C3, C6, and every 6 cycles thereafter (up to 32 months; each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Decitabine (a Metabolite Product of Guadecitabine)</measure>
    <time_frame>1, 2, 5, and 8 hours post-injection on D1 of C1 and C4, 1 hour post-injection on D1 of C2, C3, C6, and every 6 cycles thereafter (up to 32 months; each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Cohort A1: Safety Cohort (Relapsed/refractory AML)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An initial safety evaluation of the combination will be performed in 9 participants with relapsed/refractory AML. All participants will receive atezolizumab (840 milligrams [mg] IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 milligrams per square meter [mg/m^2] subcutaneously [SC] on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit (except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2: Expansion Cohort (Relapsed/refractory AML)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, an expansion cohort of 11 participants with relapsed/refractory AML (Cohort A2) will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3: Safety Cohort (Previously Untreated AML)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the combination of atezolizumab and guadecitabine is found to be safe and tolerable in Cohort A1, Cohort A3 will assess the safety and tolerability of the combination in 6 participants with untreated AML, who are older and unfit for induction chemotherapy. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4: Expansion Cohort (Previously Untreated AML)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If Cohort A3 is deemed safe and tolerable, an expansion cohort (Cohort A4) of 14 participants with untreated AML, who are older and unfit for induction chemotherapy will be evaluated. All participants will receive atezolizumab (840 mg IV on Days 8 and 22 of every 28-day cycle) administered in combination with guadecitabine (60 mg/m^2 SC on Days 1-5 of every 28-day cycle). Treatment with both study drugs will continue until loss of clinical benefit except in participants who achieve a CR, CRp, or CRi), evidence of unacceptable toxicity, voluntary withdrawal from the study, study termination, or death, whichever occurs first. Participants who achieve a CR, CRp, or CRi will receive an additional six cycles of the combination as consolidation treatment. Participants will discontinue therapy at the end of consolidation response assessment even if the CR, CRp, or CRi is maintained at that time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.</description>
    <arm_group_label>Cohort A1: Safety Cohort (Relapsed/refractory AML)</arm_group_label>
    <arm_group_label>Cohort A2: Expansion Cohort (Relapsed/refractory AML)</arm_group_label>
    <arm_group_label>Cohort A3: Safety Cohort (Previously Untreated AML)</arm_group_label>
    <arm_group_label>Cohort A4: Expansion Cohort (Previously Untreated AML)</arm_group_label>
    <other_name>MPDL3280A;</other_name>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guadecitabine</intervention_name>
    <description>Guadecitabine 60 mg/m^2 SC on Days 1-5 of every 28-day cycle.</description>
    <arm_group_label>Cohort A1: Safety Cohort (Relapsed/refractory AML)</arm_group_label>
    <arm_group_label>Cohort A2: Expansion Cohort (Relapsed/refractory AML)</arm_group_label>
    <arm_group_label>Cohort A3: Safety Cohort (Previously Untreated AML)</arm_group_label>
    <arm_group_label>Cohort A4: Expansion Cohort (Previously Untreated AML)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Life expectancy of at least 12 weeks

          -  Diagnosis of AML per World Health Organization criteria

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2

          -  Specifically, for participants in Cohorts A1 and A2: Age greater than or equal to (&gt;=)
             18 years, disease progression or failure to achieve complete or partial response after
             intensive cytotoxic therapy, participants cannot have received more than two prior
             intensive regimens (e.g., induction + consolidation and one salvage therapy +
             consolidation)

          -  Specifically, for participants in Cohorts A3 and A4: Treatment na√Øve participants
             unfit for induction chemotherapy for AML as defined by the following: Age &gt;= 70 or age
             65 to 69 years with at least one of the following: ECOG performance status of 2,
             Intermediate I/II or adverse risk cytogenetic and molecular alterations per ELN 2010
             guidelines or secondary AML, or other comorbidity judged incompatible with intensive
             chemotherapy

          -  Adequate end-organ function

          -  Willing and able to undergo a pre-treatment bone marrow aspirate and biopsy and
             subsequent bone marrow aspirates and biopsies during treatment

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive methods that result in a failure rate
             of less than (&lt;) 1 percent (%) per year during the treatment period and for at least
             30 days after the last dose of guadecitabine or 5 months after the last dose of
             atezolizumab, whichever is longer

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures, and agreement to refrain from donating sperm

        Exclusion Criteria:

          -  In Cohorts A3 and A4 only, participants with AML eligible for standard intensive
             induction therapy with an anthracycline and cytarabine

          -  Prior allogeneic stem cell transplant or solid organ transplant

          -  Active central nervous system involvement by leukemia

          -  Pregnant or lactating, or intending to become pregnant during the study

          -  History of idiopathic pulmonary fibrosis, organizing pneumonitis, drug-induced
             pneumonitis, idiopathic pneumonitis, or autoimmune disease

          -  Treatment with investigational therapy within 14 days prior to initiation of study
             drug

          -  Any approved AML-related therapy within 14 days prior to enrollment

          -  Immunosuppressive therapy within 6 weeks of Cycle 1, Day 1

          -  Daily requirement for corticosteroids (&gt; 10 mg prednisone daily or equivalent) (except
             for inhalation corticosteroids) within 2 weeks prior to Cycle 1, Day 1

          -  Prior treatment with immune checkpoint blockade therapies (anti-cytotoxic
             T-lymphocyte-associated protein 4 [anti-CTLA-4], anti-programmed death-1 [anti-PD-1]
             or anti-PD-L1) or immune agonists (anti-cluster of differentiation [CD]137, anti-CD40,
             anti-OX40)

          -  Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the
             drug, whichever is longer, prior to Cycle 1, Day 1

          -  Treatment with denosumab (or other receptor activator of nuclear factor kappa-B ligand
             [RANKL] inhibitor) 4 weeks before the first dose and for 10 weeks after the last dose
             of atezolizumab

          -  Administration of a live, attenuated vaccine within 4 weeks of Cycle 1, Day 1 or
             anticipation that such a live attenuated vaccine will be required during the study

          -  Planned major surgery during the study

          -  Positive for hepatitis C virus (HCV) antibody at screening

          -  Active hepatitis B virus (HBV) infection

          -  Positive for human immunodeficiency virus (HIV)

          -  Illicit drug or alcohol abuse within 12 months prior to screening

          -  Poor peripheral venous access

          -  Active infection

          -  Serious infection requiring hospitalization or intravenous (IV) antibiotics within 14
             days prior to enrollment

          -  Any serious medical condition or abnormality in clinical laboratory tests

          -  History or presence of an abnormal electrocardiogram (ECG)

          -  History of other malignancy within 2 years prior to screening

          -  Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells
             or any component of the atezolizumab or guadecitabine formulations

          -  History of severe allergic, anaphylactic or other hypersensitivity reactions to
             chimeric or humanized antibodies or fusion proteins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The NewYork-Presbyterian Hospital Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

